Core Insights - Medicus Pharma Ltd. is participating in the 38th Annual Roth Conference, focusing on its clinical development programs and AI-enabled drug development strategy [1][2] Group 1: Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing novel therapeutics assets [7] - The company is actively engaged in multiple countries across three continents [7] Group 2: Key Programs - SkinJect™ is a novel localized immuno-oncology product targeting non-melanoma skin diseases, particularly Gorlin Syndrome, representing a market opportunity of approximately $2 billion [3] - Teverelix is a next-generation GnRH antagonist for high-risk advanced prostate cancer patients, with a market opportunity of around $6 billion [4] Group 3: Development Strategy - The company aims to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships for late-stage development [5] - Medicus is assembling decision-grade clinical and regulatory data packages to support its partnering-focused model [5] Group 4: Recent Developments - In December 2025, the company completed enrollment of 90 patients for the Phase 2 clinical study (SKNJCT-003) evaluating D-MNA for treating BCC [15] - The company received "study may proceed" clearance from the FDA for its Phase 2b dose-optimization study of Teverelix in February 2026 [17]